SavedAdd your journal

Journals / Çocuk Dergisi / 2026 / Cilt: 15 Sayı: 3

Guillain-Barré Syndrome in Childhood

Çocukluk Çağında Guillain-Barré Sendromu

Muhammet Ali Varkal(İstanbul Üniversitesi İstanbul Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı)
Edibe Yıldız(İstanbul Üniversitesi İstanbul Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Nörolojisi Bilim Dalı)
İsmail Yıldız(İstanbul Üniversitesi İstanbul Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı)
Nur Aydınlı(İstanbul Üniversitesi İstanbul Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Nörolojisi Bilim Dalı)
Emin Ünüvar(İstanbul Üniversitesi İstanbul Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı)
Pages
89–98
Publication Date
2015-07-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Rehabilitation is greatly important for full recovery

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Guillain-Barré Syndrome is an acute inflammatory polyne- uropathy that can be seen at all ages.
📊
Key Findings & Data:Commonly symptoms originate in the lower extremities and progress upward.
💡
Conclusion & Impact:Rehabilitation is greatly important for full recovery
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Guillain-Barré sendromu · polinöropati · AIDP

Abstract

Guillain-Barré Syndrome is an acute inflammatory polyne- uropathy that can be seen at all ages. Commonly symptoms originate in the lower extremities and progress upward. The disease characterizes by symmetrical muscle weakness and loss of deep tendon reflexes. Sometimes it becomes fatal due to respiratory failure. Diagnosis is made with clinical and laboratory tests. Guillain-Barré Syndrome is a treatable disease. Full recovery can be seen in patients with advanced treatment methods. The most important cause of death is respiratory failure and serious arrhythmi- as due to autonomic involvement. Because of its progressi- ve clinical course, early diagnosis and treatment effect prognosis favourably. Intraveneus immunglobulin and plasma exchange are used in the treatment. Rehabilitation is greatly important for full recovery

Özet

Guillain-Barré Sendromu tüm yaşlarda görülebilen akut inflamatuvar bir polinöropatidir. Semptomlar genellikle alt ekstremitelerden başlayarak yukarı doğru ilerler. Simetrik kas güçsüzlüğü ve derin tendon reflekslerinin kaybı ile karakterizedir. Solunum yetmezliği nedeniyle bazen ölüm- cül olabilmektedir. Tanı, klinik ve laboratuvar testlerle konur. Guillain-Barré Sendromu tedavi edilebilir bir hasta- lıktır. Gelişmiş tedavi yöntemleri ile hastalarda tam bir iyileşme görülebilmektedir. En önemli ölüm nedeni solu- num yetmezliği ve otonom tutuluma bağlı ciddi aritmilerdir. İlerleyici bir kliniği olması nedeniyle erken tanı ve tedavi prognozu olumlu etkilemektedir. Tedavide intravenöz immunglobulin ve plazma değişimi kullanılır. Rehabilitasyonun tam düzelmede önemi büyüktür

🔖

Cite This Article

Varkal, M. A., Yıldız, E., Yıldız, İ., Aydınlı, N., Ünüvar, E. (2015). Guillain-Barré Syndrome in Childhood. Çocuk Dergisi, Cilt: 15 Sayı: 3, 89–98. https://doi.org/10.5222/j.child.2015.089

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (61)

  1. lee JH, Sung ıY, rew ıS. Clinical presentation and prognosis of childhood Guillain-Barré syndrome. J Paediatr Child Health 2008;44:449-54.
  2. https://doi.org/10.1111/j.1440-1754.2008.01325.x2.
  3. Sarnat HB. Chapter 615 Guillain-Barré Syndrome. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF (Eds) Nelson Textbook of Pediatrics. 18th edition. Philadelphia: WB. Saunders Company, 2007: 2565-6.
  4. Agrawal S, Peake d, Whitehouse WP. Management of children with Guillain-Barré Syndrome. Arch Dis Child Educ Pract Ed 2007;92:161-8.
  5. https://doi.org/10.1136/adc.2004.065706
  6. ryan MM. Guillain-Barré Syndrome in childhood. J Paediatr. Child Health 2005;41:237-41.
  7. https://doi.org/10.1111/j.1440-1754.2005.00602.x
  8. rabie M, Nevo Y. Childhood acute and chronic immune-mediated polyradiculoneuropathies. European Journal of Paediatric Neurology 2009;13:209-18.
  9. https://doi.org/10.1016/j.ejpn.2008.04.009
  10. Hughes rA, Bouche P, Cornblath dr, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflam- matory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:326-32.
  11. https://doi.org/10.1111/j.1468-1331.2006.01278.x
  12. Visser lH, van der Meche FGA, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barré syndro- me: the clinical, electrophysiologic and prognostic features. Neurology 1996;47:668-73.
  13. https://doi.org/10.1212/WNL.47.3.668
  14. Hughes rAC, Cornblath dr. Guillain–Barré syndro- me. Lancet 2005;366:1653–66.
  15. https://doi.org/10.1016/S0140-6736(05)67665-9
  16. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic fin- dings in childhood Guillain-Barré syndrome: a reappra- isal. Ann Neurol 1999;46:701-7.
  17. https://doi.org/10.1002/1531-8249(199911)46:5 3.0.CO;2-7
  18. Buompadre MC, Ga’n˜ ez lA, Miranda M, Arroyo HA. Unusual variants of Guillain–Barré syndrome in infancy. Rev Neurol 2006;42:85–90.
  19. Winer JB. Guillain-Barré syndrome. Clinical review. BMJ 2008;337:227-31.
  20. https://doi.org/10.1136/bmj.a671
  21. Ammache z, Afifi Ak, Brown Ck, kimura J. Childhood Guillain-Barré syndrome: Clinical and electrophysiologic features predictive of outcome. J Child Neurol 2001;16:477.
  22. Asbury Ak. New concepts of Guillain–Barré Syndrome. J Child Neurol 2000;15:183-91.
  23. https://doi.org/10.1177/088307380001500308
  24. rantala H, Uhari M, Niemela M. Occurrence, clini- cal manifestations, and prognosis of Guillain-Barré syndrome. Arch Dis Child 1991;66:706-9.
  25. https://doi.org/10.1136/adc.66.6.706
  26. Bradshaw dY, Jones Hr Jr. Guillain-Barré syndrome in children: Clinical course, electrodiagnosis, and prog- nosis. Muscle Nerve 1992;15:500-6.
  27. https://doi.org/10.1002/mus.880150415
  28. Jacops BC, Van doorn PA, Groeneveld JH, et al. Cytomegalovirus infection and anti-GM2 antibodys in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;62:641-3.
  29. https://doi.org/10.1136/jnnp.62.6.641
  30. rhodes kM and Tattersfield AE. Guillain-Barré syndrome associated with Campylobacter jejuni infec- tion. Br Med J 1982;285:173-4.
  31. https://doi.org/10.1136/bmj.285.6336.173
  32. ırving N, Ban MA, Tony H. Campylobacter species and Guillain-Barré syndrome clinic. Microbiol Reviews 1998;11:555-67.
  33. Ho TW, Mishu B, li CY, Gao CY, Cornblath dr, Griffin JW, et al. Guillain-Barré syndrome in northern China Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain A Journal of Neurology 1995;118(3):597-605.
  34. https://doi.org/10.1093/brain/118.3.597
  35. Asbury Ak, Cornblath dr. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:21-4.
  36. https://doi.org/10.1002/ana.410270707
  37. knebusch M, Strassburg HM, reiners k. Acute transverse myelitis in childhood: Nine cases and review of the literature. Dev Med Child Neurol 1998;40:631-9.
  38. https://doi.org/10.1111/j.1469-8749.1998.tb15430.x
  39. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001;58:913-7.
  40. https://doi.org/10.1001/archneur.58.6.913
  41. Hiraga A, kuwabara S, Ogawara k, et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barré syndrome. Neurology 2005;64: 856-60.
  42. https://doi.org/10.1212/01.WNL.0000153071.71335.E9
  43. Coşkun A, kumandaş S, Paç A, et al. Childhood Guillain–Barré syndrome. MR imaging in diagnosis and follow-up. Acta Radiol 2003;44:230-5.
  44. https://doi.org/10.1034/j.1600-0455.2003.00023.x
  45. Sladky JT. Guillain-Barré syndrome in children. J Child Neurol 2004;19:191-200.
  46. Hughes rA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain–Barré syndrome. Multidisciplinary Consensus Group. Arch Neurol 2005;62:1194-8.
  47. https://doi.org/10.1001/archneur.62.8.1194
  48. Wiffen PJ, McQuay HJ, Edwards JE, Moore rA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005;3: CD005452.
  49. https://doi.org/10.1002/14651858.cd005452
  50. korinthenberg r, Schessl J, kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barré syndrome: a randomized trial. Pediatrics 2005;116:8-14.
  51. https://doi.org/10.1542/peds.2004-1324
  52. Hughes rA, Wijdicks EF, Barohn r, et al. Practice parameter: immunotherapy for Guillain-Barré syndro- me: report of the Quality Standards Subcommittee of the American Academy of Neurology. Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736-40.
  53. https://doi.org/10.1212/WNL.61.6.736
  54. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain- Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Trial Group. Lancet 1997;349:225-30.
  55. https://doi.org/10.1016/S0140-6736(96)09095-2
  56. korinthenberg r, Schessl J, kirschner J, Schulte Mönting J. İntravenously administered immunoglobu- lin in the treatment of childhood Guillain-Barré syndro- me: a randomized trial. Pediatrics 2005;116:8-14.
  57. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain–Barré syndrome. Ann Neurol 1990; 28: 65–9.
  58. https://doi.org/10.1002/ana.410280112
  59. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341-587.
  60. Pithadia AB, kakadia N. Guillain-Barré syndrome. Pharmacological Reports 2010; 62:220-32.
  61. https://doi.org/10.1016/S1734-1140(10)70261-9